Cemiplimab Monotherapy for First-Line Treatment of Advanced NSCLC With PD-L1 of at Least 50%
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of at Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial
Lancet 2021 Feb 13;397(10274)592-604, A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, HM Turk, I Cicin, D Bentsion, O Gladkov, P Clingan, V Sriuranpong, N Rizvi, B Gao, S Li, S Lee, K McGuire, CI Chen, T Makharadze, S Paydas, M Nechaeva, F Seebach, DM Weinreich, GD Yancopoulos, G Gullo, I Lowy, P RietschelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.